K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients.
about
Does PTH offer additive value to ALP measurement in assessing CKD-MBD?Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney disease--role of sclerostin?Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism?Association of serum phosphorus variability with coronary artery calcification among hemodialysis patients.Association of relatively low serum parathyroid hormone with malnutrition-inflammation complex and survival in maintenance hemodialysis patients.Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism.Clinical management of disturbances of calcium and phosphate metabolism in dialysis patients.The five most commonly used intact parathyroid hormone assays are useful for screening but not for diagnosing bone turnover abnormalities in CKD-5 patientsAssociation between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trialBone microarchitecture in hemodialysis patients assessed by HR-pQCT.Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patientsDifferentially expressed miR-3680-5p is associated with parathyroid hormone regulation in peritoneal dialysis patients.The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: A 12-month follow-up studyCinacalcet improves control of secondary hyperparathyroidism in peritoneal dialysis: a multicenter study.The effective bioengineering method of implantation decellularized renal extracellular matrix scaffolds.In vivo regeneration of renal vessels post whole decellularized kidneys transplantation.Bone Parameters and Risk of Hip and Femur Fractures in Patients on Hemodialysis.Achievement of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative: recommended serum calcium, phosphate and parathyroid hormone values with parathyroidectomy in patients with secondary hyperparathyroidism.Calcium, parathyroid hormone, and vitamin D: major determinants of chronic pain in hemodialysis patients.(18)F-fluoride positron emission tomography measurements of regional bone formation in hemodialysis patients with suspected adynamic bone disease.Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients.Interpretation of serum parathyroid hormone concentrations in dialysis patients: what do the KDIGO guidelines change for the clinical laboratory?Trajectories of CKD-MBD biochemical parameters over a 2-year period following diagnosis of secondary hyperparathyroidism: a pharmacoepidemiological studyTarget levels for serum phosphorus and parathyroid hormone.Bone and kidney disease: diagnostic and therapeutic implications.Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.Calcitriol resistance in hemodialysis patients with secondary hyperparathyroidism.How to predict and treat increased fracture risk in chronic kidney disease.Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology.Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.Biomarkers Predicting Bone Turnover in the Setting of CKD.Cinacalcet: the chemical parathyroidectomy?Adynamic bone disease-bone and beyond.Diagnostic Workup for Disorders of Bone and Mineral Metabolism in Patients with Chronic Kidney Disease in the Era of KDIGO Guidelines.The influence of renal dialysis and hip fracture sites on the 10-year mortality of elderly hip fracture patients: A nationwide population-based observational study.Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.Parathyroidectomy-A last resort for hyperparathyroidism in dialysis patients.
P2860
Q26830747-9EAEC46A-74A9-4464-9D93-A88D429F5984Q28535084-4CC96A66-E46B-488C-A597-51FEB6B74F61Q30976543-4A09917E-D686-46CF-9293-FA48D4970F9DQ34366087-753466A3-7AFB-4CBF-905A-5A1D110F5328Q35152692-502F93DD-E446-4B53-9143-34CBEB8C8DC9Q35219236-C0722458-0B18-40BB-9D8D-88024BB68316Q35245052-ED0B0648-A71A-4019-9323-FB39C1F74BDAQ35573785-12EBB2CD-0782-474F-BADE-2BE14BD1439AQ35848015-FDEC7838-180C-4D1D-B4FE-6582AD712439Q35961696-AE046AFF-7886-4C3C-BA67-560EF0F6BA4EQ35983458-6535A157-167B-46A2-9D3A-27155B5D43E7Q36035872-418DEFE9-0BD4-4F83-993A-A494C59A9A36Q36267767-44C90C9B-7FF8-4005-88EE-2D6849CAA87CQ36337938-E696A642-1A79-4DF2-B928-EEA606E54C92Q36475574-DB00DB29-7386-46E4-8ADC-E5B6F2F1BB49Q36546582-D0486B9A-4702-4099-881B-F13F40B3D740Q36562042-ED0BB274-A0A4-4A38-8CFB-BC368144C69EQ36965098-C323B030-DF48-488C-B5D0-523EAA32578CQ36976908-5E24D7EF-E342-429B-ACC0-C57A38830D5DQ37297622-7968E6AE-6820-4836-8E78-C0E42E156E47Q37298652-57776BC4-E399-4693-8C61-5188CA914CFCQ37330304-D557B77C-9D12-4D50-88F6-0273CC8B2121Q37713739-69C0BF23-70A6-492A-86BC-C0D19E4ACE02Q37728330-C19BF067-DBA0-426E-A4CC-697F16B6EB57Q37842762-193F5B1B-B33A-4045-8636-4D3800C8B424Q37986588-9E040F63-CECB-4B13-AEBF-B4E083F222A9Q38092144-01693A38-82A6-44A4-BEB7-3DA4FF30834BQ38175317-25ECF00D-1EA3-4FFF-99A7-36B9E6F1E657Q38372851-2F80881C-01BE-4033-983D-5AE2D3FE997BQ38803449-AE4D21A1-39C4-43B9-9DBB-0FD06C7938AEQ38824573-390367C3-0EFC-485D-9BB0-AB79506D4012Q38827273-8A8BF1AA-1CAD-4B95-9816-705B1089AC81Q39239811-EAC46DBE-1054-4332-A620-BB5A838F5FF1Q39254025-745DCFEE-89BB-418F-975C-E00AF8778F42Q39719456-FCBEE594-B271-492C-B8B4-6516B47BB5A6Q40319624-7EB83553-B4A5-4D0B-8C54-C83DF144B263Q41863686-5889798F-E8DF-4845-BDEC-2A33716A526FQ41957424-534B4F74-046D-45BC-A523-B7D3B1726D55Q43437513-05FCA557-B5F3-4800-8DB8-66A62523A10FQ46652910-BE2D803C-2510-47F3-AE69-DB8CAEC41A24
P2860
K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
K/DOQI-recommended intact PTH ...... ease in hemodialysis patients.
@en
K/DOQI-recommended intact PTH ...... ease in hemodialysis patients.
@nl
type
label
K/DOQI-recommended intact PTH ...... ease in hemodialysis patients.
@en
K/DOQI-recommended intact PTH ...... ease in hemodialysis patients.
@nl
prefLabel
K/DOQI-recommended intact PTH ...... ease in hemodialysis patients.
@en
K/DOQI-recommended intact PTH ...... ease in hemodialysis patients.
@nl
P2093
P356
P1433
P1476
K/DOQI-recommended intact PTH ...... sease in hemodialysis patients
@en
P2093
A B Carvalho
D V Barreto
F C Barreto
M E F Canziani
S A Draibe
P2888
P304
P356
10.1038/SJ.KI.5002769
P407
P577
2008-01-09T00:00:00Z